<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2018">
  <stage>Registered</stage>
  <submitdate>20/06/2008</submitdate>
  <approvaldate>20/06/2008</approvaldate>
  <nctid>NCT00703482</nctid>
  <trial_identification>
    <studytitle>A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes</studytitle>
    <scientifictitle>A Randomised, Double-Blind, Placebo-Controlled Study Assessing the Effect of Fenofibrate, Coenzyme Q10 and Their co-Administration on Ventricular Diastolic Function in Patients With Type 2 Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CFEN0205</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Patients With Type 2 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10
Treatment: drugs - Fenofibrate/CoQ10

Placebo Comparator: 1 - 

Active Comparator: 2 - 

Active Comparator: 3 - 

Experimental: 4 - 

Experimental: 5 - 

Experimental: 6 - 

Experimental: 7 - 


Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate pbo/CoQ10 placebo

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate pbo/CoQ10 200 mg

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 placebo

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate 80/CoQ10 100 mg

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 100 mg

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate 80 /CoQ10 200 mg

Treatment: drugs: Fenofibrate/CoQ10
Fenofibrate 160mg/CoQ10 200 mg

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evolution of the E'/E septal ratio</outcome>
      <timepoint>End of study (V6)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Severity of the LVDD</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the Left atrium and right atrium volumes</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the Left and right sizes</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the LVEDD and LVESD</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the LVEDV and LVESV</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the LV mass</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the LV ejection fraction</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the IVRT</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the tissue Doppler E'/A' ratio</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evolution of the PV doppler parameters</outcome>
      <timepoint>End of study (V6)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Men or women aged from 40 to 79 years

          -  Patients with pre-existing T2DM

          -  HbA1C &lt;9%

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>79</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  unable to comply with the protocol, Likely to leave the trial before completion

          -  having participated in an another trial 3Ã  days before V1

          -  Pregnant or childbearing potential not using birth control method

          -  Type 1 diabetic patients, T2Dm insulin therapy

        Patients with one of the following pathology:

          -  with muscular disorders known or increase CK , or hepatic deficiency or transaminase
             increase

          -  with symptomatic gall-bladder disease or/and renal insufficiency

          -  with abnormal thyroid function

          -  with proliferative retinopathy

          -  with recent cardiovascular event, uncontrolled hypertension

          -  with known chronic alcohol intake

          -  with other severe pathology

          -  with TC&gt;= 7.0 mmol/L and/or TG&gt;= 4mmol/L at V1

          -  Patients treated with Warfarin

          -  Patients with specific ECG dysfunction</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>278</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/09/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Site 002 - Fremantle</hospital>
    <hospital>Site 003 - Nedlands</hospital>
    <hospital>Site 001 - Perth</hospital>
    <postcode> - Fremantle</postcode>
    <postcode> - Nedlands</postcode>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Solvay Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study was to study the effect of different combinations of fenofibrate
      and coenzyme Q10 on ventricular diastolic function in patients with Type II diabetes</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00703482</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Global Clinical Director Solvay</name>
      <address>Solvay Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>